Introduction. Nipple-sparing mastectomy (NSM) is increasingly used for breast cancer risk reduction and treatment. Prior small studies with variable control for baseline characteristics suggest superior satisfaction with NSM. The purpose of this study was to compare patient satisfaction following NSM and total mastectomy (TM) utilizing the BREAST-Q patient-reported outcome measure in a well-characterized patient population. Methods. Patients at a single institution undergoing NSM or TM with immediate tissue expander/implant reconstruction who completed a follow-up BREAST-Q from 2007 to 2017 were identified by retrospective review of a prospective database. Baseline characteristics were compared, and linear mixed models were used to analyze associations with BREAST-Q scores over time. Results. Of 1866 eligible patients, 219 (12%) underwent NSM, and 1647 (88%) underwent TM. Median time from baseline to BREAST-Q was 658 days. Patients with NSM were younger, more likely to be white, and had lower BMI. They more often had prophylactic surgery, bilateral mastectomies, lower-stage disease, and less often received chemotherapy/radiation than patients with TM. On multivariable analysis, after controlling for relevant clinical variables, there was no difference in satisfaction with breasts or satisfaction with outcome overall between NSM and TM patients. Psychosocial well-being and sexual wellbeing were significantly higher in the NSM group. After additionally controlling for preoperative BREAST-Q score in a subset of patients (72 NSM; 443 TM), only psychosocial well-being remained significantly higher in NSM patients. Conclusions. Patient-reported outcomes should be discussed with women weighing the risks and benefits of NSM to provide a better understanding of expected quality of life.
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Nipple-sparing mastectomy (NSM) is increasingly performed for breast cancer treatment and prophylaxis. 1 Initially described as a subcutaneous mastectomy, this technique has been refined over time and now accounts for a growing proportion of mastectomies. [2] [3] [4] Reported advantages of NSM compared with total mastectomy (TM) include improved cosmesis, body image, and nipple sensation. 5 Potential disadvantages include retained breast tissue behind the nipple-areolar complex (NAC), or elsewhere on the skin flaps or chest wall due to lack of surgical exposure, and an increased risk of mastectomy skin flap necrosis. 6 National Comprehensive Cancer Network (NCCN) guidelines endorse NSM for carefully selected patients with early-stage, biologically favorable, peripherally located cancers. 5 The primary issues to consider when recommending NSM are oncologic safety and cosmetic outcome. 7 Shortterm oncologic safety is promising, with reported rates of local recurrence at 5 years comparable to rates seen with traditional mastectomy. [8] [9] [10] [11] However, the long-term risk of local recurrence or new primary cancers is uncertain, particularly in high-risk women.
The impetus for NSM is improved cosmetic outcome. Dissatisfaction with the appearance of the nipple is common after TM and reconstruction, and preservation of the NAC results in a more natural-appearing breast. [12] [13] [14] NSM is reported to result in better patient satisfaction than TM; however, studies examining this have been limited by small sample size and variable control for differences in patient and disease characteristics. 13, [15] [16] [17] [18] The purpose of this study was to compare patient satisfaction following NSM and TM with expander/implant reconstruction utilizing a validated patient-reported outcome measure in a wellcharacterized patient population.
METHODS
Following institutional review board (IRB) approval, retrospective review of a prospectively maintained database of women undergoing mastectomy between 2007 and 2017 at a single institution was performed. Women were eligible for study inclusion if they underwent NSM or TM with immediate tissue expander/implant reconstruction and completed at least one postoperative BREAST-Q survey.
The BREAST-Q is a validated patient-reported outcome measure of satisfaction and health-related quality of life. 19, 20 It contains six domains, including three quality-oflife domains and three satisfaction domains. For the purposes of this study, we focused on the domains most likely to be affected by mastectomy type: psychosocial well-being, sexual well-being, satisfaction with breasts, and satisfaction with outcome. Psychosocial well-being assesses body image, confidence in social settings, emotional health, and self-esteem. The sexual well-being domain asks about feelings of sexual attractiveness when clothed or unclothed, and sexual confidence/comfort. Satisfaction with breasts captures body image as it relates to breast appearance clothed and unclothed. Satisfaction with outcome measures a woman's overall assessment of the outcome of her breast surgery, including whether expectations were met, the impact of surgery on her life, and satisfaction with the decision to undergo surgery (i.e., whether the woman would do it again). The domains not included were physical well-being, which measures pain and activity limitations, and satisfaction with care, which evaluates satisfaction with information provided, surgeon, medical team, and office staff. 20 Women who underwent mastectomy with reconstruction were prospectively asked to complete BREAST-Q surveys preoperatively, and at each subsequent follow-up visit. BREAST-Q scores are transformed onto a scale from 0 to 100, with higher scores representing better outcomes.
The decision to perform NSM or TM was at the discretion of the breast surgical oncologist, plastic surgeon, and patient. Patients with clinical evidence of tumor involving the NAC and those with extensive intraductal carcinoma in the subareolar space were not eligible for NSM. The surgical technique for NSM has been described previously. 13 Major complications were defined as any postoperative event that necessitated hospital admission or reoperation (including implant loss) or mastectomy skin flap necrosis greater than 10 cm. Minor complications were those managed in the office that did not require reoperation. Patients were stratified by mastectomy type (NSM vs. TM) and were analyzed with respect to age, body mass index (BMI), race, marital status, unilateral or bilateral mastectomy, indication for surgery (cancer or prophylactic), breast cancer stage, chemotherapy, radiation, postoperative complications, and preoperative BREAST-Q score.
Medians and interquartile ranges were calculated for continuous variables, and categorical variables were summarized as numbers and percentages. Between-group differences at baseline were tested using the Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables. Individual patient trajectories over time with locally weighted scatterplot smoothing (LOESS) curves overlaid were plotted for the satisfaction with breast, psychosocial well-being, sexual well-being, and satisfaction with outcome subscales of the BREAST-Q.
Linear mixed models were used to analyze associations with BREAST-Q scores over follow-up time, incorporating a random intercept and slope for each patient to account for the correlation between scores from an individual patient over time. Days from surgery to each BREAST-Q survey were calculated and analyzed longitudinally to maximize statistical power. Multivariable analysis adjusted for covariates determined a priori, including age, unilateral versus bilateral mastectomy, chemotherapy, and radiotherapy as well as baseline score if applicable. A p value \ 0.05 was considered statistically significant. All statistical analyses were conducted in R version 3.4.2 (R Core Development Team, Vienna, Austria).
RESULTS

Patient Population
During the study period, 4724 women underwent mastectomy with tissue expander/implant reconstruction, and 1869 completed at least one post-operative BREAST-Q survey and met eligibility criteria. Two patients who had unilateral NSM with contralateral TM and one patient who required NAC excision for carcinoma were excluded, leaving an analytic sample of 1866: 219 NSM and 1647 TM patients. Patient and disease characteristics are outlined in Table 1 . NSM patients were younger, had lower BMI, and more often were white. NSM patients more commonly had prophylactic surgery and underwent bilateral mastectomy. TM patients had more advanced-stage cancers and were more likely to receive chemotherapy or radiotherapy. Complications, primarily minor infections and limited mastectomy skin flap necrosis, were more common in the NSM group (minor, 15 vs. 10%; major, 4 vs. 3%, p = 0.046).
Outcomes
Median time from surgery to follow-up BREAST-Q was 658 days (interquartile range [IQR] 442-1189). Over time, satisfaction with breasts and satisfaction with outcome decreased, whereas psychosocial well-being did not change, and sexual well-being increased. Despite these trends, on univariable analysis, NSM patients had consistently higher BREAST-Q scores in all domains (Fig. 1) .
In the multivariable analysis of BREAST-Q satisfaction with breasts, there was no significant difference in scores between patients undergoing NSM and TM (Table 2) . Younger age, lower BMI, bilateral mastectomy, and not receiving chemotherapy or radiation were significantly associated with better satisfaction with breast scores. After adjustment for other variables, satisfaction with breasts decreased significantly over time.
In contrast, NSM was significantly associated with improved psychosocial well-being. Older age, lower BMI, and not receiving chemotherapy also were significantly associated with improved psychosocial well-being. Psychosocial well-being scores improved significantly over time (Table 2) .
Similarly, NSM patients had significantly better sexual well-being after adjustment for other variables. Younger age, lower BMI, and not receiving chemotherapy were associated with higher scores in the sexual well-being domain. Paralleling what was seen for psychosocial wellbeing, sexual well-being scores increased significantly over time (Table 2) . Findings for overall satisfaction with outcome resembled those seen for satisfaction with breasts. There was no significant difference between NSM and TM, and overall satisfaction with outcome decreased significantly over time. Younger age, lower BMI, and not receiving radiation were associated with higher scores (Table 2) .
Subset Analysis of Patients with Preoperative BREAST-Q Scores
Seventy-two NSM patients and 443 TM patients completed a preoperative BREAST-Q. Patients with preoperative scores were slightly younger (47 vs. 48 years, p = 0.035), more often underwent bilateral mastectomy (68 vs. 62%, p = 0.028), and more frequently had lower stage disease (stage 0 or I, 63 vs. 59%, p = 0.032) than those who did not complete a preoperative BREAST-Q. There was no significant difference in preoperative BREAST-Q scores between NSM and TM patients, although median scores were higher in NSM patients in all domains (Fig. 2) .
In multivariable analysis, after controlling for preoperative BREAST-Q score and other clinical features, no significant differences between NSM and TM were observed in satisfaction with breasts or overall satisfaction with outcome. Psychosocial well-being was significantly improved among NSM compared with TM. Sexual wellbeing did not differ significantly between NSM and TM patients, although the effect size was in the direction of improved scores for NSM versus TM over time (effect size, -4.49, p = 0.067). These results parallel the findings in the total cohort (Table 3) .
DISCUSSION
Early publications reported improved satisfaction among patients who underwent nipple reconstruction following traditional mastectomy, 12, 21 and it is now generally accepted that NSM is associated with a better cosmetic outcome than TM and reconstruction, leading to an increased patient demand for the procedure. In a study from the Mayo Clinic, the proportion of patients undergoing mastectomy and reconstruction who had NSM increased from 23.7% in 2009 to 39.7% in 2014 (p = 0.004). 1 As the indications for NSM expand, patient-reported outcomes assessing satisfaction with NSM in multiple domains are increasingly important to allow patients to assess the risks and benefits of the procedure. Our study provides a number of pertinent findings in this regard. patients undergoing NSM and TM differ significantly in characteristics that may impact satisfaction, such as age, BMI, cancer stage, and treatment received. Failure to control for these differences may result in erroneous conclusions regarding the superiority of NSM. This point is illustrated in our study where utilizing a validated patientreported outcome measure, we found no difference in satisfaction with breasts or satisfaction with overall outcome in NSM versus TM patients after adjusting for relevant clinical variables.
NSM patients had improved scores in the measured health-related quality-of-life domains. Psychosocial wellbeing, which measures body image, emotional health, and self-esteem, was higher in NSM patients. Sexual well-being scores, assessing feelings of sexual attractiveness and comfort, were significantly higher in the NSM group on multivariate analysis in the total study population, but not after controlling for preoperative BREAST-Q scores in the subset of patients who had them available. There was no significant difference in scores between NSM and TM in the patient satisfaction domains: satisfaction with breasts BMI body mass index, NSM nipple-sparing mastectomy, TM total mastectomy and satisfaction with outcome, which measure breast appearance, and overall appraisal of breast surgery outcome. 20 Consistent with prior research, bilateral mastectomy was associated with improved satisfaction with breasts on multivariate analysis. 22, 23 Several previous studies have reported improved patient satisfaction following NSM compared with TM; however, control for baseline patient characteristics, disease features, and treatment was variable. Didier et al. utilized a novel questionnaire and compared 310 women who underwent NSM with 143 women who underwent TM with NAC reconstruction. At 1 year, NSM patients reported improved body image, better satisfaction with nipple appearance and sensitivity, and a decreased sense of mutilation. However, while these groups differed at baseline, no adjustment was made for clinical or pathologic variables. 24 Metcalfe et al. utilized multiple questionnaires to evaluate satisfaction in 137 women: 53 nipple-or areola-sparing mastectomy patients, and 84 skin-sparing mastectomy patients undergoing prophylactic mastectomy for a BRCA mutation. There was no difference in perceived breast cancer risk, decision regret, or cancer-related distress, anxiety, or depression between the groups. After adjusting for time from surgery, weight, and income, they found improved satisfaction with breasts, satisfaction with outcome, and sexual well-being in the nipple-/areola-sparing mastectomy group. While this is a more homogeneous group of patients, it is a relatively small sample size with no control for preoperative satisfaction scores. 25 Similar to the findings in our study, a prior report from our institution utilizing the BREAST-Q to compare 52 NSM patients with 202 patients who underwent skin-sparing mastectomy with nipple reconstruction reported higher psychosocial and sexual well-being scores in NSM patients but no difference in satisfaction with breasts or satisfaction with outcome. There was no collection of preoperative BREAST-Q scores in this population. The findings were suggested to reflect a greater sense of normalcy and self-confidence maintained by NSM patients, despite decreased or absent nipple sensation. 13 Satteson et al. performed a systematic review and meta-analysis comparing NSM to TM with nipple reconstruction. Nine studies that included NSM patients were identified, containing satisfaction data from 473 patients. They found higher satisfaction scores in NSM patients, but there was no control for other relevant variables. 26 Not all reports have found an advantage for NSM. A small study comparing prophylactic mastectomy with immediate implant reconstruction, including 20 women with NSM and 25 women with skin-sparing mastectomy and reconstructed NAC, found no difference in patient satisfaction as measured by BREAST-Q or a body image scale. 27 Two small studies prospectively utilized the BREAST-Q preoperatively to assess satisfaction longitudinally following NSM. In 39 women who underwent NSM, satisfaction with breasts and psychosocial well-being were higher at 2 years postoperatively than at baseline. 15 In the second, 28 patients undergoing NSM had decreased satisfaction with breasts, psychosocial, and sexual well-being scores initially, which subsequently returned to baseline after 1 year. 28 These publications, coupled with the findings of our study, emphasize the importance of the time period of assessment on outcomes. While it is not surprising that outcomes are worse in the early post-treatment period where patients may still be suffering the sequelae of chemotherapy and radiotherapy, and scars have not begun to fade, we found that satisfaction with breasts and overall outcome diminishes over time in both NSM and TM patients. This may reflect a lack of satisfaction with implant-based reconstructions over time but emphasizes that retrospective comparisons between NSM and TM patients with variable lengths of follow-up have limited validity.
Strengths of this study include the evaluation of a relatively large cohort of NSM patients with the use of a validated patient-reported outcome measure with adjustment for differences in baseline patient characteristics, disease features, and treatment in this well-characterized patient population. In a subset of patients, there was also control for preoperative BREAST-Q score, allowing for a more reliable comparison between groups.
Limitations include the retrospective nature of the study. However, the BREAST-Q information was collected at the time of treatment, and the database utilized for patient identification and clinical variables is prospectively maintained. Patients were not randomized, and so selection bias exists in who received NSM or TM, although this reflects real-world clinical practice and differences were controlled for in the statistical model. Additionally, not every patient who underwent mastectomy during the study period completed a BREAST-Q survey. There may be undetected differences in women who chose to complete the BREAST-Q and those who did not, although these differences would be expected to affect NSM and TM patients similarly. The study population contained TM patients who did and did not have nipple reconstruction, and we did not specifically analyze the subset of TM patients who underwent nipple reconstruction. Lastly, the study was underpowered to detect differences in outcomes between NSM and TM due to the small size of the NSM group.
In conclusion, the decision to perform NSM versus TM should be individualized, taking the patient's preferences into account. It is imperative to provide patients with information regarding oncologic safety, complications, cosmetic outcome, as well as patient satisfaction, and set realistic expectations. Quality-of-life outcomes after NSM should be discussed with patients weighing the risks and benefits of this procedure.
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